Comments for Labiotech.eu

Comment on Is an HIV Cure Possible? The Future of HIV Therapy by Andre Camilo Douglas

Andre Camilo Douglas — Sat, 19 May 2018 12:33:00 +0000

Comment on Here Are 10 of the Hottest Biotech Hubs in Europe by Onur S. Yıldırım

Onur S. Yıldırım — Fri, 18 May 2018 10:18:00 +0000

In reply to Tommy Fanning. Trully right!

Comment on Here Are 10 of the Hottest Biotech Hubs in Europe by Dennis Fink

Dennis Fink — Fri, 18 May 2018 09:32:00 +0000

In reply to Frauke Hangen. Exactly :D

Comment on Here Are 10 of the Hottest Biotech Hubs in Europe by Tommy Fanning

Tommy Fanning — Fri, 18 May 2018 08:12:00 +0000

Where is Dublin? Home to some of the largest biotech investments in the last decade….

Comment on Series B Funding Helps Dutch Biotech Fight Graft Versus Host Disease by StefanG

StefanG — Wed, 16 May 2018 08:39:00 +0000

Great overview, however, I am missing Kiadis Pharma here. They are quite advanced in phase 3 now and their technology is simply elegant. Conditional approval could be by end of this year already so that they are leading in this field.

Comment on The First CAR-T Therapy Is Not Living Up to Commercial Expectations by dnordic

dnordic — Tue, 15 May 2018 18:45:00 +0000

CAR-T is the Wrong direction. CAR-T are only effective 6 months. Must be renewed. Not fast enough to do their job in 6 months.

Comment on Medical Cannabis Approval Sweeps Across Europe by Bella Dushner

Bella Dushner — Mon, 07 May 2018 10:28:00 +0000

Colorado is one of the lucky states in America who has been legalized the marijuana. And i don’t see any problem about this because it gives us a lot of benefits upon checking the net I saw this article https://www.worldwide-marijuana-seeds.com/blogs/marijuana-news/how-should-america-proceed-with-marijuana that Colorado is one of the few places where cannabis consumption for funsies is allowed. It’s not that way for everyone though. Cannabis is still a Schedule I drug, so naturally, this makes things a little complicated for people living in public housing, but it helps the industry also.

Comment on Needle-free diabetes care: 7 devices that painlessly monitor blood sugar by Helen Borisova

Helen Borisova — Sat, 05 May 2018 15:29:00 +0000

In reply to Clara Rodríguez Fernández. it's now 2018. Still waiting

Comment on The 10 Biotech Companies in London to Keep an Eye on in 2019 by susannah williams

susannah williams — Fri, 04 May 2018 16:50:00 +0000

For those looking for early stage funding for their biotech startup RebelBio (the world’s first early stage biotech accelerator) are now scouting for new companies to support. Applications can be made here: https://bit.ly/2I2Kqzo

Comment on The 5 Best-Selling European Drugs of 2017 by Rob Winder

Rob Winder — Fri, 04 May 2018 10:04:00 +0000

Any reason why humira the biggest selling drug is not included?
Discovered in UK by Cambridge Antibody Technology and BASF, and early development by BASF before acquisition by Abbott.

Comment on The First and Only Museum of Microbes Captivates Amsterdam by Raymond

Raymond — Thu, 03 May 2018 01:49:00 +0000

Would love to visit this place!

Comment on Update: The FDA Approves First Cannabinoid Treatment for Epilepsy by Quincy Fortier

Quincy Fortier — Tue, 01 May 2018 22:47:00 +0000

I think two years of exclusivity and then open source.

Comment on Planting the Seeds to Grow the Italian Biotech Industry by defrajac

defrajac — Mon, 30 Apr 2018 06:21:00 +0000

In reply to Labiotech.eu.

Dear Labiotech.eu,

Yes, Chiesi and Zambon are two mid-sized companies, but they don’t have enough monetary power (and the will) to start a campaign of M&A to consolidate the italian biopharma industry. Moreover, with the exception of Chiesi, which invested €340M in R&D (22% of 2016’s revenue), Italian biopharma companies don’t invest in R&D. This means they will never develop a so called blockbuster. This means they will always remain a group of good small-/mid-sized companies that manufacture drugs discovered and developed by others. We don’t even have a big generic company, like Teva or Mylan…
Maybe one day Italy will reach the level of other European countries, but all the stars must be aligned: Capital, right entrepreneurs, right management.
Nevertheless, I have hope about Italy, exactly like Sofinnova.

Comment on Top 10 biotech podcasts to follow in 2022 by Daniel

Daniel — Sat, 28 Apr 2018 18:23:00 +0000

The only One i knew from Biotech was “the cell culture dish”. I am now going to try your list, thank you vertical much!

Comment on Cancer Treatment Targeting DNA Repair is Tested in Humans for the First Time by Bull78

Bull78 — Fri, 27 Apr 2018 14:07:47 +0000

Sounds like anther PARPi

Comment on Can Gene Therapy Cure Blindness? by Herbert Sepplmayer

Herbert Sepplmayer — Fri, 27 Apr 2018 11:55:00 +0000

Two more: MeiraGTx and Athena Vision

Comment on Planting the Seeds to Grow the Italian Biotech Industry by Labiotech.eu

Labiotech.eu — Fri, 27 Apr 2018 09:26:00 +0000

In reply to Claudio De-Fraja.

Hi Claudio,

While it is true that Italy does not have big pharma, it does have two mid-sized pharma, Chiesi and Zambon. I’d say it’s not a bad starting point to try to get to the level of the other countries you mention.

Comment on New Drug for Neuropathic Pain Is Forging its Way through the Clinic by Eleanor Smith

Eleanor Smith — Thu, 26 Apr 2018 16:25:00 +0000

So good that are companies thinking towards customer.

Comment on Planting the Seeds to Grow the Italian Biotech Industry by Claudio De-Fraja

Claudio De-Fraja — Wed, 25 Apr 2018 15:42:00 +0000

UK: GSK, AstraZeneca.
Germany: Bayer, Boheringer Ingelheim, Merck Kga.
Switzerland: Novartis, Roche.
France: Sanofi.
Scandinavia: Novo Nordisk
Italy: ???
All the nations mentioned in the article have something Italy does not have: A Big Pharma industry! Without a so called anchor tenant I doubt Italy will make it. All Big Pharmas have corporate VC units/offices and all can invest or M&A, or even give grants, to small biotech companies. The Italian pharma industry is basically an industry that manufacture drugs for others and the aggregate 2016 revenues for the ten major companies was…$16B, what Roche makes in a quarter and what BI makes in a year…If some of the “big” (Menarini, Recordati, where are you?) Italian players don’t start a serious campaign of M&A in Italy with the aim to create an Italian Big Pharma, the biotech sector will always be minuscule, despite all the efforts that Sofinnova or other VCs can make.
Nevertheless I really trust Italian scientists, they do a great job even with a fraction of the resources of their American or European counterparts. They should be more trained in creating a business, and this is a gap that could be easy to fill up.

Comment on The First CAR-T Therapy Is Not Living Up to Commercial Expectations by Labiotech.eu

Labiotech.eu — Wed, 25 Apr 2018 14:41:00 +0000

In reply to FUCK THE FDA AND BIG PHARMA. Hi, I agree ideally effectiveness should be enough, but when a therapy fails commercially it can lead to its withdrawal, meaning patients no longer have access to curative technology. The article provides an outlook on what can be done to not only make the treatment profitable but also more affordable and therefore accessible to more people.